Danegaptide

Summary

Danegaptide (CHEMBL560592) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including st-elevation myocardial infarction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 291.3 Da · C14H17N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL560592
Name	Danegaptide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16656685
Molecular formula	C14H17N3O4
Molecular weight	291.3
InChIKey	BIZKIHUJGMSVFD-MNOVXSKESA-N

SMILES: C1[C@H](CN([C@@H]1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2

IUPAC name: (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid

Also known as: Danegaptida, Danegaptide, GAP-134, ZP-1609, ZP1609, DANEGAPTIDE, Danegaptide Hydrochloride

Parent form; salt/anhydrous children: CHEMBL453105

Patent coverage: 33 distinct patent families (113 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ST-elevation myocardial infarction	2	MONDO:0041656	EFO:0008585

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01977755	PHASE2	COMPLETED	Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
NCT00510029	PHASE1	COMPLETED	Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00543946	PHASE1	COMPLETED	Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
NCT00783341	PHASE1	COMPLETED	Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).